Acute Damage to the Sperm Quality and Spermatogenesis in Male Mice Exp | IJN – Dove Medical Press

Posted on by

Xiaoyu Xia,1,* Li Wang,1,* Xiao Yang,2 Yanqin Hu,1 Qiang Liu1

1Shanghai Key Laboratory of Reproductive Medicine, Department of Histoembryology, Genetics and Developmental Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, Peoples Republic of China; 2Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedics, Ninth Peoples Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Qiang LiuDepartment of Histoembryology, Genetics and Developmental Biology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, Peoples Republic of ChinaTel +86 21 63846590 Ext. 776761Email qliu0122@shsmu.edu.cn

Background: Curcumin has shown many pharmacological activities in both preclinical and clinical studies. Many technologies have been developed and applied to improve the solubility and bioavailability of curcumin, especially the nanotechnology-based delivery systems. However, there has been evidence that certain nanoparticles have potential reproductive toxicity in practice.Methods: Curcumin-poly (lactic-co-glycolic acid) (PLGA)-PEG nanoparticles (Cur-PLGA-NPs for short) were prepared. The Cur-PLGA-NPs were evaluated with its effect on the proliferation of mouse testicular cell lines in vitro and spermatogenesis in vivo, while PLGA-NPs were used as control. For animal experiments, male BALB/c mice were treated with 20 mg/kg of Cur-PLGA-NPs for continuous 10 days via tail vein injection.Results: We found the curcumin nanoparticles suppressed the proliferation of testicular cell lines in vitro. Furthermore, a short-term intravenous delivery of curcumin-loaded nanoparticles could be harmful to the differentiation of spermatogonia, the elongation of spermatids, as well as the motility of mature sperms.Conclusion: In the present study, we disclosed the acute damage on mouse spermatogenesis and sperm parameters by curcumin-loaded nanoparticles. Our results suggested that the reproductive toxicity of nanoformulated curcumin needs to be prudently evaluated before its application.

Keywords: nano-curcumin, reproductive toxicity, Sertoli cell, sperm motility, spermatogenesis

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Excerpt from:
Acute Damage to the Sperm Quality and Spermatogenesis in Male Mice Exp | IJN - Dove Medical Press

Potential impact of coronavirus outbreak on Nanomedicine Market Potential Growth, Share and Demand-Analysis of Key Players- Research Forecasts to 2024…

Posted on by

Transportation restrictions and stringent government policies are causing a downturn in the growth scale of the Nanomedicine market amidst the COVID-19 (Coronavirus) lockdown period. Hence, analysts at Market Research Reports Search Engine (MRRSE) have collated a research study that provides an in-depth outlook on Coronavirus and how the novel virus can leave long-term effects in trade practices post lockdown period in the Nanomedicine market.

Why Choose MRRSE?

Request Sample Report @https://www.mrrse.com/sample/3117?source=atm

The report on the global Nanomedicine market published by MRRSE provides a clear understanding of the flight of the Nanomedicine market over the forecast period (20XX-20XX). The study introspects the various factors that are tipped to influence the growth of the Nanomedicine market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the Nanomedicine market are analyzed in the report.

The study reveals that the global Nanomedicine market is projected to reach a market value of ~US$XX by the end of 20XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the Nanomedicine market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

Key Takeaways of the Report:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/3117?source=atm

Nanomedicine Market Segmentation

The presented study throws light on the current and future prospects of the Nanomedicine market in various geographies such as:

The report highlights the product adoption pattern of various products in the Nanomedicine market and provides intricate insights such as the consumption volume, supply-demand ratio, and pricing models of the following products:

market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report.

Porters five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.

The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 2019. Market forecast for this applications and geographies is provided for the period 2013 2019, considering 2012 as the base year.

Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.

The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

More here:
Potential impact of coronavirus outbreak on Nanomedicine Market Potential Growth, Share and Demand-Analysis of Key Players- Research Forecasts to 2024...

Global Nano Therapy Market- Industry Analysis and Forecast… – Azizsalon News

Posted on by

Global Nano Therapy Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 8.6% during a forecast period.

Market Dynamics

Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanotherapy is a branch of Nano medicine that includes using nanoparticles to deliver a drug to a given target location in the body so as to treat the disease through a process called as targeting.

This report provides insights into the factors that are driving and restraining the global Nano Therapy market. Nanotherapy is also referred to as targeted therapy, which offers to transport the molecules to the affected cells to treat the disease without affecting other negative effects on the healthy cells. Nanoparticles allow for multiple functional groups to be added to the surface. Each of the functional groups contributes to the effectiveness of this method of therapy and deliver its components in a controlled way once it gets to the target cells/tissue. Nano therapy is considered as recent technology for some diseases, which are implemented with the help of submicron-sized molecular devices or nanoparticles. Nanoparticles can improve the drug accessibility in the body with strength, drag out the medication, and can upsurge the half-life of plasma and boost the drug specificity. These are the factors driving the growth of the Nano therapy market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/54507

As compared to the conventional methods, this method has increased more popularity owing to its high accuracy when it comes to administering therapeutic formulations. The market is thriving, with around 250 Nano-medical products being verified or used for humans. Though, with Nano therapy, the carrier is protected from degradations, which allows it to reach given target cells in the body for a local reaction. Nano therapy is considerably used in the treatment of diseases like cancer, diabetes, and cardiovascular diseases. A recent study by the Journal of Diabetes and Metabolic diseases has stated that the incidence of MS ranged from 30.5 to 31.5% in China and 35.8 to 45.3% in India.

However, an absence of controlling standards in the examination of Nano therapy and high expenditure of treatment are several of the major factors that are restraining the growth of the Nano therapy market during the forecast period.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Nano Therapy Market Segment analysis

Based on Type, the Nanomaterial segment is anticipated to grow at a CAGR of 20.8% during the forecast period. The nanomaterial is the materials with at least one exterior dimension in the size range of nearly 1 to 100 nanometers. The nanomaterial is intended for developing novel characteristics and has the potential to improve quality of life. The nanomaterial is generally used in cosmetics, healthcare, electronics, and other areas currently. Unceasing development and innovation in the field are impelling the growth of the global nanomaterials market. The amazing chemical and physical properties of materials at the nanometer scale allow novel applications. For instance, energy conservation and structural strength improvement to antimicrobial properties and self-cleaning surfaces. Nanotechnology is being increasingly efficient by spending mainly on R&D activities which are resulting in the development of current technologies and innovations with reference to the new materials.

Global Nano Therapy Market Regional analysis

North America region dominated the Nano therapy market with US$ XX Mn in 2019. The availability of technology, increasing healthcare spending, and government funding for research and development are some of the factors boosting the growth of the Nano therapy market in the region. Europe is expected to follow the Americas and bring in the second leading market share for Nano therapy throughout the forecast period. Europe is mainly driven by awareness and improvement in the nanotechnology sector.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/54507

Recent Developments

In 08 May 2019- Cisplatin cis-(diammine) dichloridoplatinum (II) (CDDP) is the first platinum based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck.

In May 2019- A new study conducted by scientists from the Indian Institute of Technology, Bombay, have designed hybrid nanoparticles to treat cancer. These nanoparticles are made from gold and lipids. These nanoparticles respond to light and can be directed inside the body to release drugs to a targeted area, and are biocompatible, meaning theyre not toxic to a human body.

In September 2019, researchers at Finlands University of Helsinki, in partnership with the bo Akademi University and Chinas Huazhong University of Science and Technology developed an anti-cancer nanomedicine useful for targeted cancer chemotherapy.

The objective of the report is to present a comprehensive analysis of the Global Nano Therapy Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.The report also helps in understanding Global Nano Therapy Market dynamics, structure by analyzing the market segments and project the Global Nano Therapy Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Nano Therapy Market make the report investors guide.Scope of the Global Nano Therapy Market

Global Nano Therapy Market, By Type

Nanomaterial and Biological Device Nano Electronic Biosensor Molecular Nanotechnology Implantable Cardioverter-DefibrillatorsGlobal Nano Therapy Market, By Application

Cardiovascular Disease Cancer Therapy Diabetes Treatment Rheumatoid ArthritisGlobal Nano Therapy Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Nano Therapy Market

Selecta Biosciences Inc. Cristal Therapeutics Sirnaomics Inc. Nanobiotix Luna CytImmune Science Inc. NanoBio Corporation Nanospectra Biosciences Inc. Nanoprobes Inc. NanoBioMagnetics.n.nu Smith and Nephew NanoMedia Solutions Inc. Nanosphere Inc. DIM Parvus Therapeutics Tarveda Therapeutics

MAJOR TOC OF THE REPORT

Chapter One: Nano Therapy Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nano Therapy Market Competition, by Players

Chapter Four: Global Nano Therapy Market Size by Regions

Chapter Five: North America Nano Therapy Revenue by Countries

Chapter Six: Europe Nano Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Nano Therapy Revenue by Countries

Chapter Eight: South America Nano Therapy Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nano Therapy by Countries

Chapter Ten: Global Nano Therapy Market Segment by Type

Chapter Eleven: Global Nano Therapy Market Segment by Application

Chapter Twelve: Global Nano Therapy Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nano Therapy Market Report at:https://www.maximizemarketresearch.com/market-report/global-nano-therapy-market/54507/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

The rest is here:
Global Nano Therapy Market- Industry Analysis and Forecast... - Azizsalon News

New Approaches in Breast Cancer Therapy Through Green Nanotechnology a | IJN – Dove Medical Press

Posted on by

Menka Khoobchandani, 1, 2 Kavita K Katti, 1, 2 Alice Raphael Karikachery, 1, 2 Velaphi C Thipe, 1, 2 Deepak Srisrimal, 3 Darsha Kumar Dhurvas Mohandoss, 3 Rashmi Dhurvas Darshakumar, 3 Chintamani M Joshi, 3 Kattesh V Katti 1, 2, 4

1Department of Radiology, University of Missouri, Columbia, MO 65212, USA; 2Institute of Green Nanotechnology, University of Missouri, Columbia, MO 65212, USA; 3Dhanvantari Nano Ayushadi Pvt Ltd, Chennai 600017, India; 4Department of Physics, Department of Pharmacology, Department of Biological Engineering, University of Missouri Research Reactor (MURR), University of Missouri, Columbia, MO 65212, USA

Correspondence: Kattesh V KattiDepartment of Radiology, University of Missouri, One Hospital Drive, Columbia, MO 65212 USATel +1 573 882-5656Email KattiK@health.missouri.edu

Purpose: The overarching objective of this investigation was to investigate the intervention of green nanotechnology to transform the ancient holistic Ayurvedic medicine scientifically credible through reproducible formulations and rigorous pre-clinical/clinical evaluations.Methods: We provide, herein, full details: (i) on the discovery and full characterization of gold nanoparticles-based Nano Swarna Bhasma (henceforth referred to as NSB drug); (ii) In vitro anti-tumor properties of NSB drug in breast tumor cells; (iii) pre-clinical therapeutic efficacy studies of NSB drug in breast tumor bearing SCID mice through oral delivery protocols and (iv) first results of clinical translation, from mice to human breast cancer patients, through pilot human clinical trials, conducted according to the Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (abbreviated as AYUSH) regulatory guidelines of the Government of India in metastatic breast cancer patients.Results: The preclinical in vitro and in vivo investigations, in breast tumor bearing mice, established unequivocally that the NSB Nano-Ayurvedic medicine-gold nanoparticles-based drug is highly effective in controlling the growth of breast tumors in a dose dependent fashion in vivo. These encouraging pre-clinical results prompted us to seek permission from the Indian Governments holistic medicine approval authority, AYUSH, for conducting clinical trials in human patients. Patients treated with the NSB drug capsules along with the standard of care treatment (Arm B) exhibited 100% clinical benefits when compared to patients in the treatment Arm A, thus indicating the tremendous clinical benefits of NSB drug in adjuvant therapy.Conclusion: We have succeeded in clinically translating, from mice to humans, in using proprietary combinations of gold nanoparticles and phytochemicals to develop the Nano-Ayurvedic drug: Nano Swarna Bhasma (NSB), through innovative green nanotechnology, for treating human metastatic breast cancer patients.

Keywords: gold nanoparticles, mangiferin, mango peel, Nano Swarna Bhasma, NSB, triple negative breast tumor, pilot clinical

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post here:
New Approaches in Breast Cancer Therapy Through Green Nanotechnology a | IJN - Dove Medical Press

Nanorobotic Segments, Opportunity, Growth and Forecast By End-use Industry 2019-2020 Dagoretti News – Dagoretti News

Posted on by

Global Nanorobotic Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Nanorobotic industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2588842&source=atm

For competitor segment, the report includes global key players of Nanorobotic as well as some small players.

this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:BRUKERJEOLTHERMO FISHER SCIENTIFICGINKGO BIOWORKSOXFORD INSTRUMENTSEV GROUPIMINA TECHNOLOGIESTORONTO NANO INSTRUMENTATIONKLOCKE NANOTECHNIKKLEINDIEK NANOTECHNIKXIDEXSYNTHACEPARK SYSTEMSSMARACTNANONICS IMAGING

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeNanomanipulatorBio-NanoroboticMagnetically Guided Robot

Segment by ApplicationNanometer MedicineBiomedicalMachineOther

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2588842&source=atm

Important Key questions answered in Nanorobotic market report:

What will the market growth rate, Overview, and Analysis by Type of Nanorobotic in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Nanorobotic market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of Nanorobotic market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2588842&licType=S&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Nanorobotic product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Nanorobotic , with price, sales, revenue and global market share of Nanorobotic in 2019 and 2015.

Chapter 3, the Nanorobotic competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Nanorobotic breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, Nanorobotic market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe Nanorobotic sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read the rest here:
Nanorobotic Segments, Opportunity, Growth and Forecast By End-use Industry 2019-2020 Dagoretti News - Dagoretti News

Science Revolution Sparked by Rapid Progress in Nanotechnology – SciTechDaily

Posted on by

The ability of metallic nanoparticles to harvest and control light is transforming scientific research, according to physicists from the University of Bath.

Writing in Advanced Optical Materials, Prof Valevs team reviews the current state of nanotechnology research and discusses its likely applications in the near and medium future.

Ph.D. student Lukas Ohnoutek sees nanomedicine a branch of medicine that uses nanotechnology to improve the diagnosis and treatment of disease as a particularly buoyant area of research. On-command delivery of drugs has already proven successful in several animal trials, he says. Using this technology, medicines encapsulated in nanomaterials are directed to a specific site in the body before releasing their active ingredients in a highly controlled manner.

It is crucial to increase the efficiency of drugs and to reduce side effects, and this is something that can be achieved with on-command drug delivery, said Mr. Ohnoutek. By illuminating metal nanoparticles, it is possible to control the location, time, and amount of drug released in a patient.

Research fellow Dr. Kristina Rusimova says dramatic improvements are expected in the treatment of cancer, thanks both to on-command drug delivery and photothermal cancer therapy (PTT). PTT involves injecting nanoparticles into a patients body, where they accumulate in the tumor. When the particles are then subjected to radiation, they heat up and destroy the tumor with very little damage to surrounding tissue. In animal trials, advanced tumors have completely disappeared following photothermal therapy.

We have looked at animal trials conducted on mice, cats and dogs, said Dr Rusimova. In each case, the treatment seemed successful, which is very encouraging for treatment in humans. We know that human trials have been approved and are currently ongoing, so we are cautiously optimistic.

Other research is focused on finding nanotechnology solutions to the climate crises. There is hope that non-radiative plasmonic decay will provide a new method for improving solar cells and for producing hydrogen fuel directly from water. This process is known as water splitting. The result will be an efficient and economical low-carbon fuel, particularly suitable for heating homes and other spaces.

Other tantalizing applications for metallic nanoparticles technology include advanced biomedical imaging, improved magnetic storage and nanorobotics, where robots are manufactured with components on the nanoscale.

Prof Valev said: The tiniest metal pieces can now be formed, cut and joined with light. This allows us to integrate humanitys knowledge of metal working with our understanding of molecular self-assembly and nanoscale biotechnology. This research field offers some truly amazing perspectives for the future.

These prospects are all built around the ability of metallic nanoparticles to harvest and control light at the subwavelength scale.

Reference: Hot in Plasmonics: TemperatureRelated Concepts and Applications of Metal Nanostructures by Christian Kuppe, Kristina R. Rusimova, Lukas Ohnoutek, Dimitar Slavov and Ventsislav K. Valev, 26 November 2019, Advanced Optical Materials.DOI: 10.1002/adom.201901166

Follow this link:
Science Revolution Sparked by Rapid Progress in Nanotechnology - SciTechDaily

Canterbury father and son’s invention will revolutionise medical treatment – Stuff.co.nz

Posted on by

A typical father and son project might mean restoring a classic car or completing a home renovation, but this Christchurch pair have set their sights a little higher. LEE KENNY reports.

Phil and Anthony Butlerhave utilised cutting-edge technologyused in the hunt for the Higgs Boson to invent the world's first 3-D colour X-ray.

Phil is a professor at University of Canterbury and a Fellow of New Zealand Institute of Physics, while Anthony is a clinical radiologist and a professor at University of Otago.

Together they have created the MARS scanner, which will one day replace many of the functions of the X-ray, positron emission tomography (PET) scans and magnetic resonance imaging (MRI).

ALDEN WILLIAMS/STUFF

Phil and Anthony Butler work on an arm scanner at MARS' Christchurch laboratory.

READ MORE:* What will be the biggest scientific breakthrough of 2020?* Defence Force medic's bleeding edge invention wins Manawat's Innovate 2019* Where did the curiosity go?

The non-invasive technique will enable doctors to see colour images from inside the body, allowing them to make a more accurate diagnosis when treating everything from a broken bone to heart disease.

Phil, 72, first thought about the concept while he was atCERN (European Organization for Nuclear Research) in 2002.

Scientists working on the Large Hadron Collider used high-tech Medipix detectors to track particles and it was theorisedthey could also be used to detect X-ray photons.

Anthony joined CERN in 2005 and it was while the Butlerswere on a family holiday in Croatia that they decided to put the theory to the test.

Supplied

A 3-D image of Phil Butler's wrist taken by the MARS scanner in 2018.

They founded MARS Bioimaging in 2007 and today their 50-strong team consists of physicists, radiologists, mathematicians, biologists, engineers and computer scientists.

The company is part owned by University of Canterbury where it is based and has close ties to Otago Medical School.

Anthony, 44, explains the machine works by shining X-rays through the body and measuring the tissue composition before a computer reconstructs the information into a high-resolution 3-D colour image.

"The underlying process is often called spectral photon counting we measure the X-ray beam one photon at a time, which means we need to have very fast electronics to do this."

He says they have been looking at several medical applications for the scanners, across a range of clinical disciplines.

ALDEN WILLIAMS/STUFF

Professor Phil Butler is the chief executive of MARS Bioimaging but still takes a hands-on role.

"We've been working with orthopedic surgeons looking at fracture healing, cardiologists looking at the causes of heart disease and stroke, cancer specialists looking whether we can look at cell lines and the way they progress and we've looked at infectious diseases.

"That covers a large chunk of medicine and I expect we'll see [the scanners]hit the clinics at different times.

"It's going to be routine within a few years for a lot of point-of-care stuff."

The primary difference between the MARS scanner and other techniques is the level of detailed information it can record.

Anthony says the work is so cutting edge that components had to be built from scratch.

Dean Mouhtaropoulos

The MARS scanner was inspired by technology used at CERN, the World's Largest Particle Physics Laboratory.

"We did computer simulations to work out what we should be doing, then we had to come up with the designs, then manufacture it."

Dipanjan Pan, professor in chemical and biological engineering and radiology at University of Maryland Baltimore County, is an expert in nanomedicine and molecular imaging.

He collaborated with the MARS team for several years and says the3-D scanner has the potential to "dramatically change the ambiguity often found in black and white conventional CT imaging".

"Looking through MARS's proprietary photon counting CT 'magic lenses', you are visualising in colour the future of various biological processes as it merges with the present," he says.

"Their powerful reconstruction technique is astounding."

The technology has a range of uses from security and engineeringto physics and astronomy.

123rf

The traditional 2-D X-ray is good at showing solid objects like bones.

But the Butlers are focused on clinical applications and in July 2018 Phil became the first person to be scanned, with images generated of his wrist and ankle.

The next stage will be clinical trials next year when orthopaedic and rheumatology patients from Christchurch will bescanned.

Phil saysthe breakthrough is comparable to the first X-ray images in 1895 and the first low-resolution Computed Tomography (CT) in 1972.

"It's a major step. We went from 2-D to 3-D, now we're going from black and white to colour.

"The other thing that makes ours different from pretty much any other clinical system is we've got very high-resolution, basically 10 times the resolution of any other comparable technology."

Dr Diana Siew, associate director at MedTech Centre of Research Excellence at Auckland Bioengineering Institute, said the MARS X-ray scanner is a "game changer in medical diagnostics" because "it visualises what is happening in the body in a way that has not been achieved before".

"Different components of the body like fat, calcium, water and disease biomarkers show-up on the X-ray images in different colours, thus allowing a fuller and more accurate picture of a patient's condition," she says.

SUPPLIED

The new MRI scanner at Palmerston North Hospital had to be slotted through a hole in the wall when it was installed in April 2019.

"From a research perspective, this is exciting as it could underpin new understanding of disease onset and progression and be used to determine the efficacy of treatments.

"The MARS technology is a world's first and it is so exciting that it is happening in NZ."

As well as heralding a quantum leap in imaging capability, Anthony says the MARS technology will improve health treatment for Kiwis, as not everywhere has access to PET or MRI scanners.

"About half the people in rural New Zealand don't get appropriate cancer treatment, not because the country can't afford it but because the cancer centres are in large hospitals, the same is true for imaging," he says.

"If you are on the West Coast you cannot get a PET scan, you have to come over to Christchurch.

123RF

MRI scanners can record incredible detail but they are large and not widely available.

"So those access issues, we beat most of them because we use X-rays and they are very easy to have in a local practice, every dentist has got one."

Phil added: "One of the design goals for this system is to make it as easy to operate as a dentist's X-ray".

As well as the high cost of PET and MRI scanners, Anthony says there are other practicalities that make them less accessible.

"MRI requires rooms with big machines, you have to have liquid helium cooling it down, you can't put someone in with a pacemaker, certain vascular clips can't go in there [or] hip replacements," he says.

"With PET you have similar things, you have radioisotopes. In New Zealand we have one cyclotron in Wellington producing radioisotopes and they have to be flown around the country, so if it's a windy day in Wellington, no PET imaging can happen in the country."

Supplied

A 3-D image of Phil Butler's ankle, scanned in 2018.

MARS is operated from a secure area of University of Canterbury and as well as full-time staff, research is carried out by 15 PhD candidates.

Phil is in no doubt that a key component of the project's success is that it's based in Canterbury.

"If you look at the electronics or mechanical engineering skills of Christchurch, we can build anything," he says.

"We've got the skills to do it but the people also know each other, whereas if you go to a big city of several million, they can do it but they can't talk to their allied disciplines.

"That goes back to the farming industries, where people had to build their own machines and those skills of being able to build anything are all part of that."

Anthony agrees.

"If you go to really large research institutes they can be really skilled but they tend to have big silos. In New Zealand we tend not to operate that way.

Don Scott/Stuff

The Butlers, pictured here in 2010, examine coloured Iodine and Barium infused tissue.

"I think we're the sweet-spot in terms of size, where there's enough skill around that there's experts but we're not so big that we can't talk to each other."

Almost 15 years since the father and son team decided to embark on the research, they have made huge advances but there is still work to be done.

"If you look at where we were in 2006 or 2007 we were able to measure four colours but we had to do them one after the other, not simultaneously," Anthony says.

"We scanned the abdomen of a mouse, a pretty small object, and it [took] a day to image it and a month to do all the data reconstruction to get a picture to look at."

Day-to-day, Anthony is the company's chief medical officer and scientific lead.

Phil is the chief executive but, but according to Anthony, he still "does a lot of the technical work".

Working with family members can bring its challenges but Anthony says one of the advantages of partnering with his dad is the "innate trust" they have.

"It's actually a real pleasure," he says.

"I'm quite lucky, I didn't start working with him until I was in my early 30s, which meant I'd done all of my qualifications, established my own life.

"He had done many things himself and been pro-vice chancellor of the university and wanted to get more into practical applications so we founded this project together and that's been really nice.

"You're always going to have problems in any relationship but the fact that it's a family member gives you structure where you can actually work through problems and solve them and know that you're on the same team."

See more here:
Canterbury father and son's invention will revolutionise medical treatment - Stuff.co.nz

Tiny zaps used to kill stubborn warts – New Atlas

Posted on by

Although it's possible to remove warts by freezing them with liquid nitrogen, they often grow back, requiring multiple treatments. New research, however, suggests that ultra-short electrical pulses could be much more effective at eliminating warts and other skin lesions.

Combining the findings from multiple previous studies, scientists from California-based Pulse Biosciences recently evaluated a type of therapy known as nano-pulse stimulation (NPS). In a nutshell, it involves subjecting lesions to a series of electrical pulses, each one lasting just one nanosecond (one one-billionth of a second).

The electrical pulses create nanometer-wide pores within the cells of the lesions, through which sodium, potassium and calcium ions can enter. This in turn disrupts the flow of those same types of ions in and out of the cells, ultimately resulting in cell death.

In one test of the procedure, 174 seborrheic keratosis lesions each received a single treatment that lasted less than one minute. A few weeks later, over 82 percent of those lesions crusted over and peeled off. Because the collagen and fibrin that make up healthy skin are not affected by NPS, however, the skin that was revealed beneath the lesion sites was not scarred.

In another trial, a single NPS treatment was found to clear 99 percent of facial sebaceous gland hyperplasia lesions within 60 days. Eighteen of the lesions required a second treatment, which was most often due to the target being missed on the initial treatment.

And when NPS was used to treat 23 warts that were resistant to liquid nitrogen treatment, "a majority" of those warts died and fell off within 60 days.

"NPS technology has been shown to be very effective in the clearance of many types of cellular skin lesions while sparing the noncellular components of the dermis," states the lead scientist, Dr. Richard Nuccitelli. "The proper energies can provide scarless lesion elimination with short treatment times and very high efficacy."

A paper on the research was recently published in the journal Bioelectricity.

Source: Mary Ann Liebert, Inc.

Original post:
Tiny zaps used to kill stubborn warts - New Atlas

Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 – WhaTech Technology and Markets News

Posted on by

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to crossUS$ 720 Mn by 2026from an estimated valuation of just underUS$ 505 Mn in 2018.

This is indicative of aCAGR of 4.7%during the period2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs.

Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare.

The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer.

This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market.

Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

For Critical Insights On The Triple Negative Breast Cancer Treatment Market, Request For Customization Here @www.persistencemarketresearch.com/requesttion/14305

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy.

Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Company Profiles

For In-Depth Competitive Analysis, AccessNow @www.persistencemarketresearch.com/checkout/14305

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Continue reading here:
Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 - WhaTech Technology and Markets News

Nanomedicine Market Global Industry to Record Significant Growth in the Near Future 2019-2024 – Market Research Sheets

Posted on by

Nanomedicine Market

Global Nanomedicine Market Professional Survey Report 2019 share manufacturing companies, product type, technological progress, geographical regions, and applications 2019-2024. The Nanomedicine report looks thoroughly at company strategies, and marketing, expenditure, company planning, and sales. The outlook of this sector has been examined in conjunction with the many challenges and growth opportunities. The Nanomedicine analysis exhibits a strategic report and providing market intelligence that is accurate, trusted and vital for its merchants or to implicitly any organization.

Major Players in Nanomedicine market are:Company 1Company 2Company 3Company 4Company 5Company 6Company 7Company 8Company 9Company 10

Most important types of Nanomedicine products covered in this report are:Type 1Type 2Type 3Type 4Type 5

Most widely used downstream fields of Nanomedicine market covered in this report are:Application 1Application 2Application 3Application 4Application 5

Overview of the Report:The report begins with a market overview and moves on to cover the growth prospects of the Nanomedicine markets. Global Nanomedicine industry 2019 is a comprehensive, professional report delivering market research data that is relevant for new market entrants or established players. Key strategies of the companies operating in the markets and their impact analysis have been included in the report. Furthermore, a business overview, revenue share, and SWOT analysis of theleading players in the Nanomedicine market are available in the report.

Nanomedicine Market: Regional Analysis Includes:

Target Audience of Nanomedicine Market 2019 Forecast to 2024 Market:

The content of the study subjects, includes a total of 15 chapters:

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Contact Us:Web:www.qurateresearch.comE-mail:[emailprotected]Ph: US +13393375221, IN +919881074592

This post was originally published on Market Research Sheets

Read more from the original source:
Nanomedicine Market Global Industry to Record Significant Growth in the Near Future 2019-2024 - Market Research Sheets

Impact Investments That Create Employment and Change – CTech

Posted on by

Just like any startup company in its early stages, the biggest challenge for female entrepreneurs and those from Israel's ultra-Orthodox and Arab sectors is raising capital. These entrepreneurs typically lack tech industry networking connections from the army, school, or childhood youth movements to help them overcome the financing challenge. "Expanding support for technological initiatives of Arab and ultra-Orthodox entrepreneurs provides a tailwind to their continued successful integration into Israeli high-tech, Dr. Ami Applebaum, chief scientist at the Israeli Ministry of Economy and Industry and the chairman of the Israel Innovation Authority, said.

According to Israels Central Bureau of Statistics, although women constitute approximately one-third of the world's entrepreneurs, only 14% of Israeli businesses are owned by women and just 4% of them employ other workers. According to data provided by Tel Aviv-based research firm IVC Research Center Ltd., only 7% of the technology startup founders in Israel during the last 17 years were women. OECD data reveals that startups managed by women receive 23% less money than companies headed by men and they have a 30% lower chance of achieving an exit. Furthermore, more than half of the female entrepreneurs in the technology sector choose to influence and promote initiatives in fields considered difficult to finance public administration, health, education, and social services. One of the many reasons for this is that initiatives meeting women's and community needs encounter difficulty in recruiting funding due to a lack of familiarity or a lack of understanding of the potential involved.

Smart beauty advice and makeup tutorials

See the original post here:
Impact Investments That Create Employment and Change - CTech

Regenerative Nanomedicine Lab

Posted on by

Our recent research article "In-vitro Topographical Model of Fuchs Dystrophy for Evaluation of Corneal Endothelial Cell Monolayer Formation" appeared on theBack cover of Advanced Healthcare Materials latest issue.

Several diseases have been known to be caused by microstructural changes in the extracellular microenvironment. Therefore, the knowledge of the interaction of cells with the altered extracellular micro-structures or surface topography is critical to develop a better understanding of the disease for therapeutic development. One such disease is Fuchs corneal endothelial dystrophy (FED). FED is the primary disease and major reason of corneal endothelial cell death. If left untreated, corneal blindness will be resulted; thus, FED is the leading indication for corneal transplantation. In the USA, 4% of population over the age of 40 is believed to have compromised corneal endothelium due to FED, which will further increase due to increasing life expectancy and rapidly ageing population. A diagnostic clinical hallmark of FED is the development of discrete pillar or dome-like microstructures on the corneal endothelial basement membrane (Descemet membrane). These microstructures are called corneal guttata or guttae. Cell therapies have been proposed as an alternative treatment method for Fuchs dystrophy patients. However, currently, no in-vitro or in-vivo FED disease model is available to study the cell therapies before clinical trials.

In this study, the pathological changes in the micro-structure of basement membranes resulting from FED disease was analyzed, to identify geometrical dimension to develop an in-vitro disease model of synthetic corneal guttata pillars/domes by using microfabrication techniques. This model was used to study the monolayer formation of donor-derived human corneal endothelial cells to test the effectiveness of the corneal endothelial cell regenerative therapies. The results suggest that the corneal cell therapies may not be equally effective for patients at different stages of disease progression. The pre-existing guttata in patients could interfere with the cells thus hampering monolayer formation within the eye. Surgical removal of the guttata from the diseased Descemet membrane prior to cell regenerative therapy could increase the success rate of monolayer formation, which could potentially increase the chances of cell therapy success. This study also demonstrate how biomaterial design can be employed to mimic the pathological microstructural changes in basement membranes for better understanding of cellular responses in disease conditions.

Originally posted here:
Regenerative Nanomedicine Lab

Nano Medicine: Meaning, Advantages and Disadvantages

Posted on by

In this article we will discuss about Nano Medicine:- 1. Meaning of Nano Medicine 2. Advantages of Nano Medicine 3. Disadvantages.

The application of nanotechnology in medicine is often referred to as Nano medicine. Nano medicine is the preservation and improvement of human health using molecular tools and molecular knowledge of the human body. It covers areas such as nanoparticle drug delivery and possible future applications of molecular nanotechnology (MNT) and Nano-vaccinology.

The human body is comprised of molecules. Hence, the availability of molecular nanotechnology will permit dramatic progress in human medical services. More than just an extension of molecular medicine, Nano medicine will help us understand how the biological machinery inside living cells operates at the Nano scale so that it can be employed in molecular machine systems to address complicated medical conditions such as cancer, AIDS, ageing and thereby bring about significant improvement and extension of natural human biological structure and function at the molecular scale.

Nano medical approaches to drug delivery centre on developing Nano scale particles or molecules to improve drug bioavailability that refers to the presence of drug molecules in the body part where they are actually needed and will probably do the most good. It is all about targeting the molecules and delivering drugs with cell precision.

The use of Nano robots in medicine would totally change the world of medicine once it is realized. For instance, by introducing these Nano robots into the body damages and infections can be detected and repaired. In short it holds that capability to change the traditional approach of treating diseases and naturally occurring conditions in the human beings.

1. Advanced therapies with reduced degree of invasiveness.

2. Reduced negative effects of drugs and surgical procedures.

3. Faster, smaller and highly sensitive diagnostic tools.

4. Cost effectiveness of medicines and disease management procedures as a whole.

5. Unsolved medical problems such as cancer, benefiting from the Nano medical approach.

6. Reduced mortality and morbidity rates and increased longevity in return.

1. Lack of proper knowledge about the effect of nanoparticles on biochemical pathways and processes of human body.

2. Scientists are primarily concerned about the toxicity, characterization and exposure pathways associated with Nano medicine that might pose a serious threat to the human beings and environment.

3. The societys ethical use of Nano medicine beyond the concerned safety issues, poses a serious question to the researchers.

Go here to read the rest:
Nano Medicine: Meaning, Advantages and Disadvantages

Innovations Transforming the Global Healthcare IT, Biomarker, Biologics, and Small Molecule Landscape, 2019 Research Report – ResearchAndMarkets.com -…

Posted on by

The "Innovations Transforming the Global Healthcare IT, Biomarker, Biologics, and Small Molecule Landscape" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) provides technological insights across 26 global healthcare innovations.

The technologies analyzed include advances in digital health, biologics, small molecules, medical imaging, dental caries and precision oncology platforms. The TOE also covers application and megatrends impact, apart from exclusive analyst insights for each innovation.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Companies featured:

For more information about this report visit https://www.researchandmarkets.com/r/98ey4z

View source version on businesswire.com: https://www.businesswire.com/news/home/20191218005393/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read more from the original source:
Innovations Transforming the Global Healthcare IT, Biomarker, Biologics, and Small Molecule Landscape, 2019 Research Report - ResearchAndMarkets.com -...

Nano-sized drug carriers could be the future for patients with lung … – Phys.Org

Posted on by

July 3, 2017 by Ryan O'hare Nanomedicine could help patients with fatal lung conditions. Credit: Imperial College London

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

Scientists based at Imperial College London have tested a new type of nanoparticle called metal organic frameworks (MOF) tiny metal cages less than 100 nanometres across that can be loaded with drug molecules which they believe could potentially be used to treat patients with a devastating condition called pulmonary arterial hypertension (PAH).

In PAH the blood vessels of the lungs constrict and thicken, increasing blood pressure and causing the right side of the heart to work harder and harder, until it eventually fails. The condition is rare but devastating and can affect people of all ages, including babies, young adults and the elderly. Patients in the late stage of the disease have few treatment options beyond transplant, with a mean survival time of around five years following diagnosis.

While there is no cure for PAH, existing treatments work by opening up these blood vessels. These drugs act on blood vessels throughout the body, however, causing blood pressure to drop and resulting in a number of side effects which means the dose at which these drugs can be given is limited.

In their latest study, published online in Pulmonary Circulation, the multidisciplinary group at Imperial describes how it has taken the first in a number of steps to develop nanoparticles which could deliver drugs directly to the lungs, showing that the basic structures are not harmful to cells.

Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial, who led the research, said: "The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects. For patients with pulmonary arterial hypertension, it could mean we are able to turn it from a fatal condition, to a chronic manageable one."

Metallic cages for drug delivery

The tiny metallic structures composed of iron were made in the lab of Professor Paul Lickiss and Dr Rob Davies's, from the Department of Chemistry and by Dr Nura Mohamed during her PhD studies at Imperial. Dr Mohamed, who was funded by the Qatar Foundation, made the structures so existing drugs used to treat PAH could fit inside them.

These structures were tested in human lung cells and blood vessel cells, which were grown from stem cells in the blood of patients with PAH. The team found that the structures reduced inflammation and were not toxic to the cells.

Further tests showed that the MOFs were safe in rats, with animals injected with MOFs over a two-week period showing few side effects other than a slight build-up of iron in the liver.

"One of the biggest limitations in nanomedicine is toxicity, some of best nanomedicine structures do not make it past the initial stages of development as they kill cells," said Professor Mitchell. "We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells."

MOFs are an area of interest in nanomedicine, with engineers aiming to develop them as carriers which can hold onto drug cargo, releasing it under specific conditions, such as changes in pH, temperature, or even when the nanostructures are drawn to the target area by magnets outside the body.

Beyond the finding that their iron nanostructures were non-toxic, the team believes the MOFs may have additional therapeutic properties. There was evidence to suggest anti-inflammatory properties, with the MOFs reducing the levels of an inflammatory marker in the blood vessels, called endothelin-1, which causes arteries to constrict. In addition, iron is also a contrast agent, meaning it would show up on scans of the lungs to show where the drug had reached.

The MOFs have not yet been tested in patients, but the next step is to load the tiny metallic structures with drugs and work out the best way to get them to target their cargo to the lungs. The researchers are confident that if successful, the approach could move to trials for patients, with a drug candidate ready to test within the next five years. The MOFs could potentially be delivered by an inhaler into the lung, or administered by injection.

"In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung," explained Professor Mitchell. "This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery."

Explore further: Longer-lasting pain relief with MOFs

More information: Nura A. Mohamed et al. Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy, Pulmonary Circulation (2017). DOI: 10.1177/2045893217710224

To treat headaches, back pain or fever, most of us have reached for ibuprofen at one point or another. But we often have to take doses every four to six hours if the pain warrants it. Now scientists are working on a way to ...

People with a lung scarring condition that leaves them fighting for breath could be helped by a new medication, research suggests.

A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for ...

(HealthDay)Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant.

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary ...

(Medical Xpress) -- Scientists at UCD have identified a potential new treatment for life-threatening complications associated with chronic obstructive lung diseases like emphysema and chronic bronchitis. Chronic obstructive ...

In today's increasingly powerful electronics, tiny materials are a must as manufacturers seek to increase performance without adding bulk.

A team led by Gang Han, PhD, has designed a human protein-based, tumor-targeting Magnetic Resonance Imaging (MRI) contrast that can be easily cleared by the body. The discovery holds promise for clinical application, including ...

AMOLF researchers have developed nanoscale strings whose motion can be converted to light signals with unprecedented strength. This could allow for extremely precise sensors and comes with an important side effect. "Analogous ...

Scientists have created new 2-D nanostructured surfaces which appear as realistic 3-D objects including shading and shadows - using cutting edge nano-engineering.

One afternoon, Carnegie Mellon University Materials Science and Engineering (MSE)'s Mohammad Islam walked into colleague Paul Salvador's office and asked what the biggest problem was in photocatalysis that he'd like to be ...

As embedded intelligence is finding its way into ever more areas of our lives, fields ranging from autonomous driving to personalized medicine are generating huge amounts of data. But just as the flood of data is reaching ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Follow this link:
Nano-sized drug carriers could be the future for patients with lung ... - Phys.Org

Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence … – MilTech

Posted on by

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs. Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables. Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Global nanomedicine market is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others. Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future. Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

A Sample of this Report is Available Upon Request @http://www.persistencemarketresearch.com/samples/6370

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period. However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

Request to View Tables of Content @http://www.persistencemarketresearch.com/toc/6370

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

To Know About Latest Report Click Here:http://www.persistencemarketresearch.com/market-research/healthcare-nanotechnology-nanomedicine-market.asp

See the original post here:
Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence ... - MilTech

Lungs in space: research project could lead to new lung therapeutics – Phys.Org

Posted on by

Space travel can cause a lot of stress on the human body as the change in gravity, radiation and other factors creates a hostile environment. While much is known about how different parts of the body react in space, how lungs are affected by spaceflight has received little attention until now, say researchers at The University of Texas Medical Branch at Galveston and Houston Methodist Research Institute.

That will change, though, once their research project, which aims to grow lungs in space, reaches the International Space Station. UTMB and HMRI researchers say what they learn from the study could have real implications for astronauts, as well as those still on Earth, and could lead to future therapeutics.

"We know a lot about what happens in space to bones, muscle, the heart and the immune system, but nobody knows much about what happens to the lungs," said Joan Nichols, a professor of Internal Medicine and Microbiology and Immunology, and associate director for research and operations for the Galveston National Laboratory at UTMB. "We know that there are some problems with lungs in space flight, but that hasn't been closely looked into. We hope to find out how lung cells react to the change in gravity and the extreme space environment, and then that can help us protect astronauts in space, as well as the lungs of regular people here on Earth."

This investigation represents the third of four collaborative projects currently active at the HMRI's Center for Space Nanomedicine. The center, directed by Alessandro Grattoni, chairman and associate professor of the Department of Nanomedicine at HMRI, focuses on the investigation of nanotechnology-based strategies for medicine on Earth and in space. The research is supported by the Center for the Advancement of Science in Space, NASA and HMRI.

Scientists from UTMB and HMRI prepared bioreactor pouches that include lung progenitor and stem cells and pieces of lung scaffolding. The scaffolding is the collagen and elastin frame on which lung cells grow. Space X successfully launched the payload containing these pouches Aug. 14 on its 12th Commercial Resupply Services mission (CRS-12) from NASA's Kennedy Space Center in Florida and is expected to arrive at the International Space Station Aug. 16. Once on the ISS, the cells are expected to grow on the scaffold in a retrofitted bioreactor.

Once the lung cells have returned to Earth, researchers will look for the development of fibrosis, the structure of the tissues and the response of immune cells, among other changes and damage that could occur to the lung cells. Lung injuries have been found to accelerate in space, and it is through close study of those cells that therapeutics hopefully could be developed.

Nichols and Dr. Joaquin Cortiella, a professor and director of the Lab of Tissue Engineering and Organ Regeneration at UTMB, have successfully grown lungs in their lab in Galveston, but now they will see if astronauts can do the same in zero gravity. Jason Sakamoto, affiliate professor and former co-chair of the Department of Nanomedicine at HMRI, has applied his novel organ decellularization process and nanotechnology-based delivery systems to support this overall lung regeneration effort.

"We have experience working with the Center for the Advancement of Science in Space to study our nanotechnologies in action on the International Space Station," Grattoni said. "However, we are extremely excited to be a part of this clinical study, since it may play a pivotal role in how we approach future space travel in terms of preserving astronaut health. What we learn during this fundamental experiment could lead to science-fiction-like medical advancements, where organ regeneration becomes a reality in both deep space and here on Earth."

Researchers at HMRI will take the results from UTMB and work on developing therapeutics that could help astronauts, as well as people on Earth.

"This exploration will provide fundamental insight for the collaborative development of cell-based therapies for autoimmune diseases, hormone deficiencies and other issues," Grattoni said.

Explore further: Image: Testing astronauts' lung health

Excerpt from:
Lungs in space: research project could lead to new lung therapeutics - Phys.Org

Sudden resignation of ERC president stirs heated dispute over motives – Science Business

Posted on by

Mauro Ferrari resigned unexpectedly as president of the European Research Council, triggering a noisy public spat over why and how he left.

Ferrari, an Italian-American expert in nano-medicine, fired off an angry resignation memo provided first to the Financial Times castigating the European Commission for a largely uncoordinated cluster of initiatives. He said he pushed to have the ERC, which focuses on frontier research, launch a special funding round for COVID-19 research. As a result, he said, I have lost faith in the system itself and submitted his resignation on 7 April.

But that version of events was quickly disputed in Brussels. Christian Ehler, a German member of the European Parliament who leads research legislation, issued a late-night statement calling Ferraris actions a window-dressing public relations stand on the coronavirus crisis and it was a contradiction to the legal basis of the ERC.

Other sources said the agencys governing body, the 21-member Scientific Council, had decided days earlier to ask for Ferraris resignation. Among the issues was a belief that he was spending too much time on non-ERC, private activities.

The Commission issued a statement confirming Ferraris immediate resignation and noting that his contract as ERC president only gave him the legal powers of a special advisor to the Commission. Legally, it said, the Scientific Council defines the scientific funding strategy and methodologies of the ERC. It went on to thank him for the strong personal investment he made in the months leading up to his appointment 1 January.

When he took office on 1 January, Ferrari was allowed to continue some outside activities back in the US, where he had built his career in engineering, nanotechnology and medicine. Among these was a paid board position at a US biotech company, Arrowhead Pharmaceuticals. He also continued as an affiliate professor in pharmaceutical science at the University of Washington. But the arrangement was unusual for an agency like the ERC, and had already prompted some outside criticism. As European nations began entering COVID-19 lockdown last month, he was in the US, where his grown children work.

A Commission spokesman late on 7 April confirmed Ferraris resignation, but declined to elaborate. Ferrari couldnt be reached immediately for direct comment, but the Financial Times published his statement excoriating the ERC and the Commission.

In the statement, he said that he proposed that the ERC set up a special COVID-19 programme, because at a time like this, the very best scientists in the world should be provided with resources and opportunities to fight the pandemic. He said it was rejected unanimously by the Scientific Council without even considering what shape or form it may take. He added that he was later invited by Commission President Ursula von der Leyen for my input on COVID-19, which created an internal political thunderstorm inside the Commission bureaucracy.

The ERC, by law, funds research proposed directly by scientists based on their own judgment of whats important; they get the money - 2.2 billion in all for 2020 if peer review panels organised by the agency agrees with them. Ferraris statement says he knew his idea for top-down COVID-19 grants ran counter to the agencys normal bottom-up practice, but it was justified by the emergency.

Agency officials declined to comment publicly, but the MEP, Ehler, issued a public defence of the ERC, pushing back at Ferrari.

Besides calling Ferraris COVID-19 plan window-dressing, Ehler said Ferrari was never really acquainting with the independent nature of the ERC. He continued: We are sorry that things have turned out this way for a brilliant researcher and entrepreneur like Mr. Ferrari. However, this should not serve as argument to accuse the ERC or the EU of not doing enough.

The ERC focuses on fundamental rather than applied research and numbers among its existing grantees virologists, epidemiologists and others who have been doing basic research for the agency, and have now joined applied COVID-research teams in the Commissions other programmes.

They include 48.5 million for emergency Horizon 2020 collaborative projects for vaccines, cures and tools; 45 million to its Innovative Medicines Initiative; 80 million in financial support for German vaccine maker Curevac; and up to 164 million in grants to small business with COVID-19 solutions to develop.

On taking office in January, Ferrari quickly unveiled ambitious plans for the ERC. In an interview with Science|Business in February, he spoke enthusiastically of the need for what he called super-disciplinary research, in which scientists break out of their normal disciplines and think across domains. He was also a strong advocate of researchers helping to get their discoveries commercialised and into widespread use something he did repeatedly in his own career.

Ferrari, now 60 years old, is credited as one of the founders of nanomedicine. In 2016, his research team made headlines with a new cancer treatment that uses nanoparticles loaded with a chemotherapeutic to target metastatic cells directly, thereby minimising collateral damage to healthy tissue and allowing more sustained and aggressive treatment. Ferrari has around 480 publications to his name, with over 20,000 citations. He also holds dozens of patents for inventions including different varieties of nanoparticles for drug delivery.

Originally from northern Italy, he studied mathematics at the University of Padua before moving to University of California, Berkeley, where he studied for a masters and a PhD in mechanical engineering. He went on to become an associate professor at Berkeley and moved into medicine when he became a professor of bioengineering and mechanical engineering at Ohio State University.

Ferrari later moved to the MD Anderson Center and the University of Texas Health Science Center in Houston. In 2010 he became president and CEO of the Houston Methodist Research Institute.

Excerpt from:
Sudden resignation of ERC president stirs heated dispute over motives - Science Business

The Benefits of Tech Even Those That Don’t Cut Costs – The Tech Report

Posted on by

Technology makes processes easier, faster, safer, and more efficient. Shouldnt it, therefore, also reduce costs?

This isnt always the case. Thats because researching and developing new technology can cost millions of dollars; add to that the cost of materials and production. By the time that technology is launched, billions may have been spent developing it.

New technology has brought immense benefits to the following four industries, but it hasnt necessarily lowered costs for consumers.

Medical technology is so innovative that doctors can now insert tiny robotics into the body to repair internal wounds or remove objects. This is a branch of medicine called nanomedicine. Nanomedicine uses nanosized (even smaller than microsized) carriers to transport drugs to specific cells or tumors in the body. This form of technology opens up a new way to treat cancer, for instance. Rather than subject the entire body to chemotherapy, nanotechnology can deliver chemotherapy drugs directly to the tumor.

These types of treatments, however, dont come cheap. In fact, healthcare costs in the United States continue to rise. In 2018, the U.S spent $3.6 trillion on healthcare, which works out to an average of $11,000 per person. This is projected to increase to $18,000 per person by 2028.

One of the main drivers of escalating healthcare costs is medical technology. According to a report by The Hastings Center, healthcare economists found that 40 percent to 50 percent of annual healthcare cost increases were linked to new medical technologies.

Sustainable energy has a positive impact on the environment. Solar- and wind-powered energy mean less reliance on harmful fossil fuels for energy production. Electric cars eliminate toxic fuel emissions.

But solar panels can be costly to install, and electric cars are often more expensive to buy than traditional cars. Electric vehicles can range in pricing from $31,915 for a Nissan Leaf to $70,875 for the Jaguar I-Pace.

The good news is these products pay for themselves over time with the savings on your electric and gas bills. In addition, buying an electric car or implementing energy-saving technology in your home can make you eligible for a rebate. States like California offer rebates of up to $500 when installing solar products and up to $7,000 when buying an electric vehicle.

Many of the aviation safety systems that are standard on planes today were born from past mistakes. When an airplane crashes, a thorough investigation is conducted. The lessons learned from a catastrophic disaster often lead to improved safety technology.

The aviation industry has made giant strides in technology to make flying safer, lower the cost of fuel, and find ways to reduce airplane emissions. Engineers are looking at ways to manufacture lighter engines and using 3D printing to design and produce lighter aircraft parts. Every part that becomes lighter, even brackets and hinges, helps decrease the planes overall weight and boost fuel efficiency.

In their quest to reduce their carbon footprint, aircraft manufacturers are following the example of the automotive industry and testing electric engines for airplanes. Theyre also testing biofuels, such as sugarcane and cooking oil. According to NASA, a 50/50 blend of jet fuel and biofuel can cut soot emissions by 50 percent. While this is great for the environment, flying a plane with biofuels costs more than traditional jet fuel.

Despite new technology and lower fuel costs, travelers are unlikely to see a drop in the cost of flights. And with the COVID-19 pandemic grounding planes across the globe, many airlines are likely to try to recoup losses by charging higher fares when travel resumes.

Car safety technology, like collision avoidance systems, blind-spot monitoring, automated braking, lane keep assist, and rear-view backup cameras have become standard on most new cars.

Despite the fact that the National Highway Traffic Safety Administration and the Insurance Institute for Highway Safety agree that safety tech in cars is effective in reducing car crashes, insurance companies havent lowered their rates on cars that feature them. The only car safety technologies that lower insurance rates are electronic stability control and telematics.

If car tech helps prevent accidents, why arent insurance rates lower? Insurance companies cite the following reasons:

Technology improves our lives in many ways, but it doesnt always lower costs. In some cases, it may even increase the cost of goods or services. The tradeoff is in what we gain from new technologies: more efficiency, better safety, time-saving convenience, and less damage to the environment.

Visit link:
The Benefits of Tech Even Those That Don't Cut Costs - The Tech Report

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update – BioSpace

Posted on by

After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given NBTXR3s universal mode of action, our proof-of-concept in soft tissue sarcoma, and promising results from our phase I trial in head and neck cancers, we are confident that NBTXR3 activated by radiation therapy has the potential to significantly improve treatment outcomes for head and neck cancer patients. Beyond head and neck, we will continue to expand into additional indications and combination therapies. Ultimately, we aim to change the oncology treatment paradigm for millions of patients around the world. Laurent Levy, CEO of Nanobiotix

NANOBIOTIX (Euronext : NANO ISIN : FR0011341205 the Company) today announced its global development strategy for 2020 and beyond, following proof-of-concept (POC) and European market approval for NBTXR3 in locally advanced soft tissue sarcoma of the extremities and trunk wall (Brand Name: Hensify) in 2019. The Company will continue to prioritize its registration pathway in the US and EU for the treatment of head and neck cancers, while also working to advance the Nanobiotix immuno-oncology (I/O) program and evaluate NBTXR3 in other indications such as lung, pancreatic, esophageal, hepatocellular carcinoma (HCC), prostrate, and rectal cancers. To execute this plan, Nanobiotix will focus on H&N cancers while its collaborators (i.e. The University of Texas MD Anderson Cancer Center (MD Anderson) in the US and PharmaEngine in Asia) are working on other indications.

Global Development Plan Visualization

TRIAL

STATUS

ANTICIPATED NEXT STEPS

Development in Head and Neck Moving Forward

Phase III Registration Trial for NBTXR3 in head and neck patients ineligible for cisplatin

TRIAL NAME: STUDY 312

Nanobiotix trial

Design completed based on last interactions with FDA and European payers (EUnetHTA)

Jan 2020 - Submission of final protocol to FDA and other global regulatory bodies

Phase I and Phase I Expansion Trial for NBTXR3 in head and neck patients ineligible for cisplatin or intolerant to cetuximab

TRIAL NAME: Study 102/ 102 Expansion

Nanobiotix trial

Phase I dose escalation completed / data reported 19 patients

Dose Expansion 38 of 44 patients recruited

Q1 2020 - Update of dose escalation patients follow-up

Mid 2020 - First expansion phase data on efficacy and safety of dose expansion

Phase I/II Trial for NBTXR3 combined with cisplatin for head and neck patients

TRIAL NAME: PEP503-HN-1002

PharmaEngine trial

3rd dose level recruiting

H2 2020- Last patient in for 5th (last) dose level

Immuno-Oncology Program with NBTXR3

Phase I Basket Trial for NBTXR3 combined with pembrolizumab or nivolumab in H&N, lung metastasis, liver metastasis patients

TRIAL NAME: Study 1100

Nanobiotix trial

First patients treated

Protocol extended to include patients with lung and liver metastases from any primary tumor. Recruitment ongoing

Mid-year 2020 - first data reported

Phase II Trial of reirradiation with NBTXR3 combined with anti-PD-1/L1 for inoperable, locally advanced HN cancer

Phase II Trial for NBTXR3 combined with anti-PD-1 or anti-PD-L1 in Stage IV lung cancer

Phase I Trial for NBTXR3 combined with anti- CTLA4 and anti-PD-1 or PD-L1 in patients with advanced solid tumors and lung or liver mets

Phase II Trial for NBTXR3 for recurrent/metastatic HNSCC patients with limited PD-L1 expression

MD Anderson trials

Final stage of protocol development

Q2-Q3 2020 - Submission of protocols to FDA

Development Across Other Indications

Phase I Trial for NBTXR3 in hepatocellular carcinoma and liver metastasis patients

TRIAL NAME: Study 103

Nanobiotix trial

Recruitment of the last patient at the 5th (last) dose level (one patient left to be treated)

Q1 2020 - Update on results

Phase I Trial for NBTXR3 in prostate cancer patients

TRIAL NAME: Study 104

Nanobiotix trial

2nd dose level recruiting

Q4 2020 - Update on results

Phase I Trial for NBTXR3 in pancreatic cancer

Phase I Trial for NBTXR3 in lung cancer patients in need of reirradiation

Phase I Trial for NBTXR3 in esophageal cancer patients

MD Anderson trials

Pancreas Regulatory process ongoing

Lung re-irradiation / Esophageal Submission of final protocol to regulatory process

Q2 2020 - First patient treated in pancreas

Q3 2020 - Lung re-irradiation / Esophageal first patient treated

Phase I/II Trial for NBTXR3 combined with chemotherapy in rectal cancer patients

TRIAL NAME: PEP503-RC-1001

PharmaEngine trial

4th (last) dose level recruiting

H2 2020 - Report phase I results

Next Steps in Soft Tissue Sarcoma

Phase III Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients

TRIAL NAME: Act.In.Sarc

Nanobiotix trial

Trial completed / data reported

H2 2020- Further follow up of the patients

Post-Approval Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients

TRIAL NAME: TBD

Nanobiotix trial

Design established (100 patients)

H2 2020 - Trial authorization by the relevant regulatory bodies expected

Development in Head and Neck Moving Forward

There are approximately 700,000 new head and neck cancer patients worldwide each year300,000 of these patients reside in the US and the European Union (EU) 1. Of these patients at diagnosis, 90% suffer from local disease and the remaining 10% have metastatic disease. 70-80% of all Head and Neck patients will receive radiation therapy, but significant unmet medical needs remain regarding either local control, systemic control, toxicity, or some combination of the three2. This is especially challenging for patients ineligible for platinum-based chemotherapy (cisplatin).

Global Registration Trial for NBTXR3 in Head and Neck Patients Ineligible for Cisplatin

As previously announced, Nanobiotix has begun interacting with the US Food and Drug Administration (FDA) on its regulatory pathway and met with the agency in October 2019 to refine the design elements of Study 312a phase III investigators choice, dual-arm, randomized (1:1) global registration trial including elderly head and neck cancer patients who are ineligible for platinum-based chemotherapy (cisplatin).

More than half of head and neck cancers include large primary tumors which may invade underlying structures and/or spread to regional nodes. Treatment of these locally advanced forms of the disease ordinarily requires aggressive, concerted measures. Due to potential comorbidities and toxicities associated with treatment, elderly and frail patients suffer from limited therapeutic options. Study 312 aims to target the unmet needs of this population.

Patients in the control arm will receive radiation therapy with or without cetuximab (investigators choice), and patients in the treatment arm will receive NBTXR3 activated by radiation therapy with or without cetuximab (investigators choice). The trial will recruit around 500 patients, the initial readout will be based on event-driven progression-free survival (PFS), and the final readout will be based on PFS and overall survival (OS). The study will be powered to demonstrate the OS superiority of NBTXR3 activated by radiation therapy. In addition, quality of life (QoL) will be measured as a key secondary outcome.

The Companys next step is to submit the final trial design to FDA and other global regulatory bodies within the month. A futility analysis is expected 18 months after the first patient is randomized, the interim analysis for PFS superiority is expected at 24-30 months, and final analysis will report on PFS and OS. In the event of favorable data from the initial readout, Nanobiotix plans to apply for conditional registration in the US.

Confirming Efficacy with Phase I (Study 102) Expansion

Nanobiotix has already reported promising early signs of efficacy for patients with head and neck cancer through Study 1023 a phase I trial of NBTXR3 nanoparticles activated by intensity-modulated radiation therapy (IMRT) in the treatment of advanced-stage head and neck squamous cell carcinoma (HNSCC). The patient population for Study 102 includes elderly and frail patients who are ineligible for cisplatin or intolerant to cetuximab.

As a result of this report, the Company launched an expansion cohort with 44 additional patients to strengthen preliminary efficacy data. Recruitment for the expansion cohort has reached 38 of 44 patients and the initial readout is expected by mid-2020. Depending on the favorability of the final expansion phase data, the Company may seek to expedite the regulatory process in the EU.

Additional Development in Head and Neck with Collaborators

To serve as many head and neck cancer patients as possible and as mentioned above, the Company has engaged in ongoing clinical collaborations with MD Anderson in the US and PharmaEngine in Asia.

The Company is collaborating with MD Anderson on nine (9) clinical trials across multiple indications, three (3) of which are expected to evaluate head and neck cancer in patient populations outside of the trials Nanobiotix is executing alone (e.g. borderline resectable, inoperable and neck cancer (re-irradiation), etc.)

Follow this link:
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update - BioSpace